Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review
NHSC
Record Status
This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
Citation
NHSC. Adalimumab (Humira) for moderate to severely active Crohn's disease - horizon scanning review. Birmingham: National Horizon Scanning Centre (NHSC). 2005
Authors' objectives
This study aims to summarise the currently available evidence on adalimumab (Humira) for moderate to severely active Crohn's disease
Authors' conclusions
Adalimumab (Humira) is a fully human anti-tumour necrosis factor (TNF)-alpha monoclonal antibody in phase III trials for the induction and maintenance of clinical remission and response in patients with moderate to severely active Crohn's disease (Crohn's Disease Activity Index - CDAI score 220 - 450). It is administered by subcutaneous injection. Results from one phase III placebo-controlled, randomised trial, published in abstract, show a significant increase in clinical remission at 4 weeks versus placebo (from 12% to 24-36%). A randomised extension trial in patients who responded is assessing maintenance of remission. A 24-week open-label extension trial in patients who did not respond by 4 weeks, found a remission rate of 33.2% and a response rate of 78.2%. A one-year ongoing phase III trial in 830 patients is due to complete in Q3 2006.
Department of Public Health&Epidemiology, The University of Birmingham, Edgbaston, Birmingham B15 2TT, United Kingdom. Tel: +44 121 414 7831; Fax: +44 121 414 2269; Email: c.packer@bham.ac.uk